UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on On Assignment

Loading...
Loading...
In a report published Friday, BMO Capital Markets reiterated its Outperform rating on On Assignment
ASGN
, and slightly raised its price target from $23.00 to $24.00. BMO Capital noted, “The ‘upside surprise' (at least versus our estimates) was mainly margin driven, as revenues of $388.3 million was just above $382-$388 million guidance, while adjusted EBITDA margins increased to 11.7% from 11.2% in 3Q11 – well above our 11.1% estimate and the highest since 2001. ASGN is dominated by its technology offerings (roughly 75% of revenues), which grew y/y (pro forma) in the high teens, by our estimates – likely faster than the market. Its healthcare and physician offerings (15% of revenues) are also showing solid growth as those sectors come back to life. While Life Sciences (10% of revenues) is struggling owing to a challenging environment, ASGN's diversification strategy is helping to offset that. While the company is not immune from the slower growth facing the sector, we still believe ASGN has and will continue to take share.” On Assignment closed on Thursday at $19.48.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsBMO Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...